Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.

  title={Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.},
  author={Martin I. Surks and Eduardo Ortiz and Gilbert H. Daniels and Clark T. Sawin and Nananda F. Col and Rhoda H. Cobin and Jayne A. Franklyn and Jerome M. Hershman and Kenneth D Burman and Margo A. Denke and Colum A. Gorman and Richard S. Cooper and Neil Weissman},
  volume={291 2},
CONTEXT Patients with serum thyroid-stimulating hormone (TSH) levels outside the reference range and levels of free thyroxine (FT4) and triiodothyronine (T3) within the reference range are common in clinical practice. The necessity for further evaluation, possible treatment, and the urgency of treatment have not been clearly established. OBJECTIVES To define subclinical thyroid disease, review its epidemiology, recommend an appropriate evaluation, explore the risks and benefits of treatment… 

Tables from this paper

Thyroid testing and management of hypothyroidism during pregnancy: a population-based study.

The local guidelines are variable and poorly compliant with international guidelines, performance of thyroid testing is not optimal, and rates of elevated TSH at testing are extremely high in subgroups.

Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range.

Common variation in persons with thyroid function in the normal range are associated with adverse health outcomes, and data suggest, by extrapolation, that carefully monitored treatment of even modest elevations of TSH may have substantial health benefits.

Clinical practice guidelines for the management of hypothyroidism.

These evidence-based clinical guidelines on hypothyroidism will provide unified criteria for management of hyp Timothyroidism throughout Latin America.

Management strategies for patients with subclinical hypothyroidism: a protocol for an umbrella review

It is anticipated that the findings of this umbrella review will aid in the development of consensus-based clinical recommendations for subclinical hypothyroidism, as well as highlight areas for future research.

Why are GPs treating subclinical hypothyroidism? Case note review and GP survey

It is suggested that GPs are uncertain how to interpret symptoms and TFT results in older individuals with considerable variation in management of SCHo between GPs with some GPs treating patients outside of all guideline recommendations.

Subclinical thyroid disease.

Meta-analyses have provided epidemiological data in cardiovascular mortality and morbidity in subclinical thyroid disease and a randomized controlled trial is needed to identify those subjects identified from screening programmes that benefit from intervention in terms of morbidity and mortality.

The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

There is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism, but the task force concluded that there are no data to support treatingSHyper in younger asymptomatic patients with grade 1 Shyper.

Screening for thyroid dysfunction and treatment of screen-detected thyroid dysfunction in asymptomatic, community-dwelling adults: a systematic review

Moderate to very low-quality evidence is found on the benefits and harms of treatment for subclinical hypothyroidism, with most of the evidence showing no benefit of treatment.

Subclinical hypothyroidism in children

Thyroid replacement therapy is not justified in children with subclinical hypothyroidism when Thyroid stimulating hormone is <10 mIU/L, and an algorithm for managing this condition is suggested.

The clinical significance of subclinical thyroid dysfunction.

The mechanisms underlying tissue alterations in SCTD and the effects of replacement therapy on progression and tissue parameters are examined, and the issue of the need to treat slight thyroid hormone deficiency or excess in relation to the patient's age is addressed.



American Thyroid Association guidelines for detection of thyroid dysfunction.

The American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum thyrotropin concentration, beginning at age 35 years and every 5 years thereafter.

Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies.

It is demonstrated that only a part of the cohort of patients with subclinical hypothyroidism develops overt hypothyrogenism over time and that a major group remains in the subclinical state after 10 yr and that the value of predictive factors in the development of overt thyroid failure is analyzed.

Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.

It is suggested that T4 therapy in individuals with mild thyroid failure lowers mean serum total and LDL cholesterol concentrations, and the reduction in serum total cholesterol may be larger in Individuals with higher pretreatment cholesterol levels and in hypothyroid individuals taking suboptimal T4 doses.

Thyroid disease in the elderly. Part 2. Predictability of subclinical hypothyroidism.

Thyroid status could not be predicted from clinical signs and symptoms in this sample of elderly community-dwelling patients, substantiates the difficulty of diagnosing subclinical hypothyroidism in the elderly based solely on clinical features.

The Colorado thyroid disease prevalence study.

The results confirm that thyroid dysfunction is common, may often go undetected, and may be associated with adverse health outcomes that can be avoided by serum TSH measurement.

Is a more active attitude warranted in patients with subclinical thyrotoxicosis?

Therapy should be considered more often than previously in patients with nodular goitre and subclinical thyrotoxicosis, particularly in conjunction with atrial fibrillation, the results of a 2‐year follow-up investigation suggest.

Current status and performance goals for serum thyrotropin (TSH) assays.

If manufacturers and laboratories collaborate to solve the sensitivity and specificity problems discussed here, clinical laboratories should be better able to consistently deliver reliable serum TSH measurements across the full range of TSH concentrations encountered in clinical practice.

Elevations of thyroid-stimulating hormone during acute nonthyroidal illness.

The results of thyroid function tests, including serum TSH, obtained during acute nonthyroidal illness should be interpreted cautiously, and screening for thyroid disorders among elderly patients with acute illnesses is not warranted.

Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment.

Thyroxine prescription was common in the four general practices sampled, although indications for its use were appropriate, and abnormal serum levels found in those prescribed thyroxine for hypothyroidism were found to be high.

The treatment of subclinical hypothyroidism is seldom necessary.

On initial assessment, it appears that the position advocating l -thyroxine therapy for most subjects with SH enjoys strong experimental support, however, careful scrutiny of the entire spectrum of primary data bearing on the question of whether or not SH should be treated with l - thyroxine yields a legitimate con-trary view.